Shuai Wu

• Twelve years' academia plus three years' industry research experience in cancer epigenetics/metabolism/target therapy, microbiology and gene editing.
• Experienced in gene editing technologies including RNA editing, DNA editing and large gene integration.
• Experienced in oncology precision medicine including synthetic lethality screening, target ID/validation and MoA.
• Experienced in developing and optimizing experimental protocols in terms of biochemistry and molecular biology assays, including long/short read seq such as AmpSeq, HT RNA-seq, ChIP-seq, Hi-C, HiChIP, ATAC-seq, CUT&RUN, ONT, CRISPR screening and genome editing screening.
• Demonstrated abilities to collaborate and take leadership within and outside academic setting through team and project management.

• Twelve years' academia plus three years' industry research experience in cancer epigenetics/metabolism/target therapy, microbiology and gene editing.
• Experienced in gene editing technologies including RNA editing, DNA editing and large gene integration.
• Experienced in oncology precision medicine including synthetic lethality screening, target ID/validation and MoA.
• Experienced in developing and optimizing experimental protocols in terms of biochemistry and molecular biology assays, including long/short read seq such as AmpSeq, HT RNA-seq, ChIP-seq, Hi-C, HiChIP, ATAC-seq, CUT&RUN, ONT, CRISPR screening and genome editing screening.
• Demonstrated abilities to collaborate and take leadership within and outside academic setting through team and project management.

Ph.D., Biochemistry and Molecular Biology, Shanghai Institute of Biochemistry and Cell Biology, University of Chinese academy of sciences, Shanghai, China